

#### TECHNICAL REPORT ON THE EVALUATION OF THE BIDS EVALUATED BY MEANS OF SUBJECTIVE VALUE-BASED CRITERIA FOR THE CONTRACT RELATING TO THE HIRING A SERVICE OF SHOTGUN METAGENOMICS SEQUENCING OF NUCLEIC ACIDS EXTRACTED FROM BIOLOGICAL SAMPLES AS PART OF COMPETITIVE PROJECTS IMPLEMENTED IN THE FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR).

Co-financed by the "Fondo Europeo de Desarrollo Regional" (FEDER).



## 2022-034 SERVICES FOR SEQUENCING OF NUCLEIC ACIDS (PI20/00130)

On July 25 2022 has been valued, in accordance with the criteria established in the bidding conditions, the bid submitted by the company participating in this bidding process for the contracting of the service of shotgun metagenomics sequencing of nucleic acids extracted from fecal samples, part of the Project PI20/00130 titled "Inflammatory Bowel Disease and Microbiome: Diagnosis and prediction of disease activity from the lab to the patients" of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR), funded by the Instituto de Salud Carlos III (Ministerio de Ciencia, Innovación y Universidades).

The tender subject of these minutes, was published in the Contracting Party Profile of our website on June 28<sup>th</sup> 2022, and the maximum date for the submission of bids according to the minimum deadlines set forth in Law 9/2017, of November 8, Public Sector Contracts, ended last July 13<sup>th</sup> 2022 until 13:00h.

As stated in the Minutes of Constitution of the Contracting Committee and of the Opening of Envelope No. 1 dated July 15<sup>th</sup> 2022, the documentation submitted by **Novogene UK Company Limited**, did not contain any remediable defects.

On July 22<sup>nd</sup> 2022, the opening of the envelope containing the bid evaluated by means of criteria subject to value judgment was carried out, as stated in the Minutes of Constitution of the Contracting Committee and of the Opening of Envelope No. 2.

The scoring and motivation of the bids, which have been reproduced taking into account the specifications contemplated in the Specific Administrative Clauses, shall be detailed below, in accordance with the following scoring table:

### 1. Criteria that can be assessed through value judgments......up to 40 points.

### TECHNICAL OFFER

The following criteria can be assessed through value judgments. The value will be done in compared with the tenders submitted. The highest score will be given to the offer that best fits the technical requirements set out in this document. All other bids will be scored proportionally



by comparison. Subsequently, the various proposals evaluated in descending order will be sorted out, and the following formula will be applied to obtain the score,

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}}$$

 $P_{op}$ = Score the offer to value P = Criteria score  $VT_{op}$ = Technical evaluation of the scored offer  $VT_{mv}$ = Technical evaluation of the best scored offer

The following criteria will be evaluated by value judgments. The award criteria for assessing the contents of envelope N. ° 2 are as follows:

```
1.1 Drafting of work proposal.....(up to 30 points)
```

It must include:

•	Report on sample processing (DNA quality and quantity)	10 points
		40 11

- Quality of the sequences with Phred scores higher than Q30.....10 points
  Timelines for shipments of sequences ......10 points
- 1.2 Memory of experience.....(up to 10 points)

Bidders must present a report of experience explaining their participation in clinical trials.

- Presentation of the organization ("About" information) ......3 points
- Number of sequencing projects handled by the company......4 points

A <u>minimum total score of 26 points</u> is required in the technical assessment so that the bidding companies can continue in the selection process and opt for the criteria that can be evaluated with automatic formulas. <u>Failure to obtain 26 points or more in the technical bid will be excluded from this tender procedure.</u>

In view of the foregoing, the score that has been achieved is shown below:



# 1.1 Drafting of work proposal.....(up to 30 points).

	Novogene UK Company
Report on sample processing (DNA quality and quantity) Up to 10 points	10
Quality of the sequences with Phred scores higher than Q30 Up to 10 points	10
Timelines for shipments of sequences Up to 10 points	9
TOTAL	29

## Justification of the valuations:

The company reported high quality procedure of sample processing using a combination of electrophoresis gel and Qubit for quality control of samples, and using protocol for library preparation as it is recommended by the Illumina platform. They will deliver a high Pred Quality score (Q30) as expected, and their sequence delivery timing is quite reasonable. They also provided 2 options for sequence delivery, either by hard disk or by digital form.

1.2 Memory of experience.....(up to 10 points)

	Novogene UK Company
Presentation of the organization ("About" information) Up to 3 points	2.8
Experience Up to 3 points	3



Number of sequencing projects handled by the company Up to 4 points	4
TOTAL	9.8

Bidders must present a report of experience explaining their participation in clinical trials.

### Justification of the valuations:

Novogene has presented a detailed and adequate information in regards to their company history and activities. Indeed, they implanted their laboratory in many countries including the USA, China, Singapore and the UK. They have collaborated with various large clinical metagenomic projects and have co-authors high-impact factors papers in the microbiome field. Their experience in sequencing appears therefore undeniable and the number of sequencing projects is impressive.

Consequently, the scoring table for the value judgment criteria is as follows:

VALUE JUDGMENT TABLE		
Bidder:	40% - Value Judgment	
Novogene UK Company	38.8	

Once the bidding company has been evaluated and the score has been arranged in descending order, the following formula is applied to obtain the score for each item evaluated,



$$P_{op} = P x \frac{VT_{op}}{VT_{mv}}$$

 $P_{op}$ = Puntuación de la oferta a Puntuar P= Puntuación del criterio  $VT_{op}$ = Valoración Técnica de la Oferta que se Puntúa  $VT_{mv}$ = Valoración Técnica de la oferta Mejor Valorada

## 1.1 Drafting of work proposal.....(up to 30 points).

Report on sample processing (DNA quality and quantity).....Up to 10 points

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}} = 10$$

	Novogene UK Company
Report on sample processing (DNA quality and quantity) Up to 10 points	10

Quality of the sequences with Phred scores higher than Q30.....Up to 10 points

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}} = 10$$

	Novogene UK Company
Quality of the sequences with Phred scores higher than Q30 Up to 10 points	10

Timelines for shipments of sequences......Up to 10 points

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}} = 10$$

Novogene UK Company



Timelines for shipments of sequences	Up to 10 points	10

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}} = 3$$

	Novogene UK Company
Presentation of the organization ("About" information) Up to 3 points	3

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}} = 3$$

		Novogene UK Company
Experience	Up to 3 points	3

Number of sequencing projects handled by the company......4 points

$$P_{op} = P x \frac{VT_{op}}{VT_{mv}} = 4$$

Novogene UK Company
4



Consequently, after applying the formula, the final scoring table for the value judgment criteria is as follows,

FINAL VALUE JUDGMENT TABLE	
Bidder:	40% - Value Judgment
Novogene UK Company	<mark>40</mark>

Below is the table of scores for the technical offers, which will be completed with the economic part presented by each company, once the public opening of envelope No. 3 takes place, which will be on August 02<sup>nd</sup> 2022, at 10:00h, through Microsoft Teams with the Digital Envelope tool, as announced in the bases of this tender published on the website of the VHIR.

SCOREBOARD						
Bids submitted	Economic Offer			60% Automatic formulas	40% Value judgments	
	BI	IVA	TOTAL			TOTAL
Novogene UK Company					40	40

Barcelona, July 25th 2022.

RESPONSABLE Mr. Chaysavanh Manichanh Head of the Microbiome Group Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)